Gland Pharma Share Price Jump 5% After USFDA Approval for Eye-Allergy Drug

Gland Pharma share price (NSE: GLAND) climbed nearly 5% on Thursday after the company received approval from the US Food and Drug Administration (USFDA) for an eye-allergy drug. The stock touched ₹1,790.40, its highest level since December 3, 2025, on the NSE.

By 9:49 am, the stock was trading 1.61% higher at ₹1,735.90, while the Nifty 50 slipped 0.29%.

Despite today’s jump, Gland Pharma shares are still down 6.38% over the past one year.

Why Did Gland Pharma Share Price Rise Today?

The stock gained after the USFDA approved Olopatadine Hydrochloride Ophthalmic Solution USP (0.7%), an over-the-counter medicine used to treat eye allergies.

The drug is considered therapeutically equivalent to Pataday One-Day Relief 0.7%, sold by Alcon Laboratories.

Market Opportunity For The Drug

Globally, the market size for Olopatadine Hydrochloride Ophthalmic Solution was estimated at $1.32 billion in 2025. It is expected to grow at a 7.2% CAGR between 2025 and 2033, supported by the rising cases of eye allergies and conjunctivitis.

In India, companies such as Alchem Laboratories, Alembic Pharmaceuticals and Lupin, apart from Gland Pharma, also have USFDA approvals for this drug.

Also Read: Government Leans on Dividends as IDBI Bank Sale Becomes Key to FY26 Capital Receipts!

About Gland Pharma

Founded in 1978, Gland Pharma is one of the largest injectable drug manufacturers, with a presence in over 60 countries. The company mainly operates under a B2B business model.

Conclusion

Gland Pharma’s sharp rise reflects positive sentiment after the USFDA approval for its eye-allergy drug. While the long-term outlook depends on sustained momentum, the stock may remain volatile in the near term as it tests key resistance levels.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.